Heart failure with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent form of heart failure, accounting for nearly half of all heart failure cases. Despite its significance, HFpEF remains a challenging condition to manage and treat, as effective therapies have been limited. In this article, we delve into the landmark clinical trials that […]
Tag: irbesartan
AIMS Trial Summary: Irbesartan in Marfan Syndrome
2019 AIMS TRIAL Irbesartan in Marfan syndrome Placebo-controlled, double-blind randomised trial Objective: To evaluate an angiotensin receptor blocker (ARB) compared with placebo among patients with confirmed Marfan syndrome. 192 patients Inclusion criteria: Patients with clinically confirmed Marfan syndrome, 6-40 years of age, aortic Z score of >0. Patients with prior or planned cardiac surgery and […]